Price$16.26-0.48 (-2.87%)
01:45 PM07:45 PM
News · 26 weeks83-69%
2026-01-182026-07-12
Mix3890d
- Insider21(55%)
- Other12(32%)
- SEC Filings3(8%)
- Earnings2(5%)
Latest news
25 items- PRBausch + Lomb Launches EyeGility™ Inserter Preloaded IOL Delivery System in the United StatesEyeGility is designed for the enVista® family of IOLs Offers balanced push force for smooth delivery, convenient one-handed operation Available now for enVista Aspire™; will be available for enVista Envy™ in the coming months Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of the EyeGility™ Inserter preloaded IOL delivery system. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716234280/en/ "The enVista IOL platform has long been appreciated by surgeons for its glistening-free optic and differentiated
- PRBausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective CandidatePhase 2 study did not meet its primary endpoint. Company will discontinue development of eye drops for glaucoma-related vision improvement but continue pursuing a sustained-release implant for the treatment of vision-threatening disease with a primary focus on geographic atrophy. Portfolio continues to include more than 60 assets under development, with multiple anticipated milestones over the next few months. Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from its Phase 2 study evaluating BL1107 in patients with glaucoma. The study did not achieve its primary end
- PRBausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient CareDesigned to reduce the operational burden that stands between physicians and their patients. Initial offering focuses on pre-surgery cataract education, with additional AI capabilities for ophthalmology planned over time. Brand agnostic and built to serve all eye care providers. Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the creation of Orphia™, a new AI-powered digital health platform built on the belief that eye care providers should spend less time managing disconnected tools and technologies and more time caring for patients. The platform is brand agnostic and designed to
- PRBausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter financial results on Wednesday, July 29, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, July 29, 2026 Time: 8 a.m. ET Webcast: https://www.webcaster5.com/Webcast/Page/2883/53394 Partic
- INSIDERPresident, Surgical Bonnefoy Luc covered exercise/tax liability with 1,008 shares, decreasing direct ownership by 1% to 87,023 units (SEC Form 4) to satisfy tax liability4 - Bausch & Lomb Corp (0001860742) (Issuer)
- SECSEC Form SD filed by Bausch + Lomb CorporationSD - Bausch & Lomb Corp (0001860742) (Filer)
- PRBausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops in the United StatesBlink Triple Care Preservative Free eye drops are made with the same clinically proven formula as Blink Triple Care and provide up to 10 hours of dry eye symptom relief‡ Delivers clinically proven 3-in-1 extended relief,† providing instant, long-lasting dry eye symptom relief and locking in moisture Further strengthens Bausch + Lomb's position in the dry eye category Will be available at most retailers by the end of June 2026 Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Blink Triple Care Preservative Free eye drops, which provide instant, long-lasting reli
- INSIDERDirector Von Eschenbach Andrew C. was granted 15,842 shares, increasing direct ownership by 22% to 86,656 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERDirector Ross Thomas W. Sr. was granted 15,842 shares, increasing direct ownership by 23% to 85,233 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERDirector Robertson Russel C was granted 15,842 shares, increasing direct ownership by 20% to 94,260 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERDirector Paulson John was granted 15,842 shares, increasing direct ownership by 21% to 89,823 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERDirector Ling Karen was granted 15,842 shares, increasing direct ownership by 35% to 61,518 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERDirector Kavanagh Sarah B was granted 15,842 shares, increasing direct ownership by 30% to 69,541 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERDirector Collis Steven H was granted 15,842 shares, increasing direct ownership by 61% to 42,003 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERDirector Bernier Nathalie D. was granted 15,842 shares, increasing direct ownership by 23% to 85,505 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERDirector Alfonso Eduardo was granted 15,842 shares, increasing direct ownership by 104% to 31,072 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERChairman of the Board and CEO Saunders Brent L covered exercise/tax liability with 2,886 shares, decreasing direct ownership by 0.29% to 978,389 units (SEC Form 4) (withholding tax)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- PRBausch + Lomb to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceBausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders and Chief Medical Officer and Head of Research and Development Yehia Hashad, MD, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL, on Tuesday, June 9, 2026, at 1:20 p.m. ET. A live webcast of the session will be available on the Investor Relations section of the Bausch + Lomb website. About Bausch + Lomb Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we've evolved with the changi
- PRBausch + Lomb Announces 2026 Annual Meeting of Shareholder ResultsBausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2026 annual meeting of shareholders (the "Annual Meeting") held on May 20, 2026. The detailed results of the vote for the election of directors are set out below: Name For Against Broker Non-Votes Eduardo Alfonso, M.D. 331,573,622 4,244,069 11,452,072 Nathalie Bernier 331,522,655 4,295,036 11,452,072 Steven H. Collis 331,575,559 4,242,132 11,452,072 Sarah B. Kavanagh 331,548,740
- SECSEC Form 8-K filed by Bausch + Lomb Corporation8-K - Bausch & Lomb Corp (0001860742) (Filer)
- PRBausch + Lomb Launches PreserVision AREDS3™ Eye Vitamins in the United StatesPreserVision AREDS3™ eye vitamins combine clinically proven AREDS2 nutrients recommended by the National Eye Institute (NEI) to help reduce the risk of moderate-to-advanced age-related macular degeneration (AMD) progression with a unique B-vitamin complex* The most advanced PreserVision formula intended to support a broader range of people including those in earlier stages* Triple‑action formula supports macular health: protects, nourishes and boosts* PreserVision AREDS3 was informed by a growing body of scientific evidence on B vitamins in AMD,*2 with a long‑term clinical trial now in planning Now available at most retailers nationwide Bausch + Lomb Corporation (NYSE/TS
- INSIDEREVP and CFO Eldessouky Sam covered exercise/tax liability with 63,938 shares, decreasing direct ownership by 16% to 343,192 units (SEC Form 4) (for tax liability)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDEREVP of R&D and CMO Hashad Yehia covered exercise/tax liability with 13,664 shares, decreasing direct ownership by 8% to 166,377 units (SEC Form 4) to satisfy withholding obligation4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERSVP, Controller and CAO Munsch Frederick covered exercise/tax liability with 8,673 shares, decreasing direct ownership by 9% to 89,640 units (SEC Form 4) (withholding tax)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERPresident, Surgical Bonnefoy Luc covered exercise/tax liability with 11,970 shares, decreasing direct ownership by 12% to 88,031 units (SEC Form 4) to cover withholding tax4 - Bausch & Lomb Corp (0001860742) (Issuer)
BLCO FAQ
7 questionsWhat does Bausch + Lomb Corporation do?
Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic...Where does BLCO stock trade?
Bausch + Lomb Corporation (BLCO) is listed on NYSE.What sector and industry is BLCO in?
Bausch + Lomb Corporation operates in the Health Care sector, Ophthalmic Goods industry.When did Bausch + Lomb Corporation go public?
Bausch + Lomb Corporation (BLCO) completed its IPO in 2022.What are analysts saying about BLCO?
Bausch + Lomb Corporation has had 8 recent analyst actions on file. The most recent action was from Evercore ISI: In-line with a $1800.00 price target on 2026-01-05. Recent price targets range from $1500.00 to $2200.00.What companies are similar to BLCO?
Notable peers in the same industry include ALC (Alcon Inc.), COO (The Cooper Companies Inc.), WRBY (Warby Parker Inc.), EYE (National Vision Holdings Inc.), STAA (STAAR Surgical Company). Compare BLCO side-by-side with any of them on Quantisnow.How can I track BLCO on Quantisnow?
Quantisnow aggregates Bausch + Lomb Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BLCO to receive live email and push alerts on every new disclosure.